Abstract
We assessed the efficacy and safety of a 1adrenoceptor antagonist (Urapidil) alone or combined with an antimuscarinic (oxybutynin or propiverine) in patients diagnosed with detrusor hyperactivity with impaired contractile function (DHIC). Forty patients with urodynamically proven DHIC were stratified into 2 groups, namely group 1 receiving Urapidil only and group 2 receiving Urapidil plus oxybutynin or propiverine for a 12-week treatment regimen. A total of 40 patients, including 16 in group 1 and 24 in group 2 were treated and 40 (100.0%) completed the 12 weeks of treatment. Significant improvement was noted in both group 1 (75.0%) and group 2 (62.5%) after treatment. Voiding difficulty and urinary urgency improved significantly in all patients of both group 1 and group 2. The results of this study suggest that a i-adrenoceptor antagonist alone or combined with an antimuscarinic represents an effective and relatively safe treatment modality for patients with DHIC.
| Original language | English |
|---|---|
| Pages (from-to) | 16-20 |
| Number of pages | 5 |
| Journal | Nishinihon Journal of Urology |
| Volume | 74 |
| Issue number | 1 |
| Publication status | Published - Jan 2012 |
Fingerprint
Keywords
- DHIC
- Drug therapy
ASJC Scopus subject areas
- Urology
Cite this
Clinical investigation of drug therapy for cases of detrusor hyperactivity with impaired contractile function. / Ohashi, Teruhisa; Takenaka, Tadasu; Sako, Sinichi; Kondo, Katsuyoshi; Watanabe, Toyohiko; Kumon, Hiromi.
In: Nishinihon Journal of Urology, Vol. 74, No. 1, 01.2012, p. 16-20.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical investigation of drug therapy for cases of detrusor hyperactivity with impaired contractile function
AU - Ohashi, Teruhisa
AU - Takenaka, Tadasu
AU - Sako, Sinichi
AU - Kondo, Katsuyoshi
AU - Watanabe, Toyohiko
AU - Kumon, Hiromi
PY - 2012/1
Y1 - 2012/1
N2 - We assessed the efficacy and safety of a 1adrenoceptor antagonist (Urapidil) alone or combined with an antimuscarinic (oxybutynin or propiverine) in patients diagnosed with detrusor hyperactivity with impaired contractile function (DHIC). Forty patients with urodynamically proven DHIC were stratified into 2 groups, namely group 1 receiving Urapidil only and group 2 receiving Urapidil plus oxybutynin or propiverine for a 12-week treatment regimen. A total of 40 patients, including 16 in group 1 and 24 in group 2 were treated and 40 (100.0%) completed the 12 weeks of treatment. Significant improvement was noted in both group 1 (75.0%) and group 2 (62.5%) after treatment. Voiding difficulty and urinary urgency improved significantly in all patients of both group 1 and group 2. The results of this study suggest that a i-adrenoceptor antagonist alone or combined with an antimuscarinic represents an effective and relatively safe treatment modality for patients with DHIC.
AB - We assessed the efficacy and safety of a 1adrenoceptor antagonist (Urapidil) alone or combined with an antimuscarinic (oxybutynin or propiverine) in patients diagnosed with detrusor hyperactivity with impaired contractile function (DHIC). Forty patients with urodynamically proven DHIC were stratified into 2 groups, namely group 1 receiving Urapidil only and group 2 receiving Urapidil plus oxybutynin or propiverine for a 12-week treatment regimen. A total of 40 patients, including 16 in group 1 and 24 in group 2 were treated and 40 (100.0%) completed the 12 weeks of treatment. Significant improvement was noted in both group 1 (75.0%) and group 2 (62.5%) after treatment. Voiding difficulty and urinary urgency improved significantly in all patients of both group 1 and group 2. The results of this study suggest that a i-adrenoceptor antagonist alone or combined with an antimuscarinic represents an effective and relatively safe treatment modality for patients with DHIC.
KW - DHIC
KW - Drug therapy
UR - http://www.scopus.com/inward/record.url?scp=84863296870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863296870&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84863296870
VL - 74
SP - 16
EP - 20
JO - Nishinihon Journal of Urology
JF - Nishinihon Journal of Urology
SN - 0029-0726
IS - 1
ER -